While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.
Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q1 2025 Results Conference Call April 24, 2025 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Raul Parra - Chief Financial Officer and Treasurer Brian Lloyd - Chief Legal Officer & Corporate Secretary Conference Call Participants Jason Bednar - Piper Sandler Steve Lichtman - Oppenheimer Robbie Marcus - J.P. Morgan Craig Bijou - Bank of America Securities David Rescott - Baird Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Jon Young - Canaccord Mike Matson - Needham Jayson Bedford - Raymond James Operator Welcome to the Merit Medical Systems First Quarter 2025 Earnings Conference Call.
Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merit Medical (MMSI) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.77 per share a year ago.
Beyond analysts' top -and-bottom-line estimates for Merit Medical (MMSI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MMSI launches the Ventrax Delivery System, enhancing pulmonary access procedures with improved control, precision, and efficiency for interventionalists.
Merit Medical (MMSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Merit Medical's strong product portfolio raises optimism about the stock.